Canada – Information Note – Information Note regarding dsRNA-based pesticides

Pest Management Regulatory Agency

4 January 2024

Table of Contents

About dsRNA
Current uses
Current regulatory status
Current actions
For more information

The purpose of this information note is to communicate the current regulatory status of double-stranded ribonucleic acid (dsRNA)-based pesticides, and the current approach to their regulation under the Pest Control Products Act by Health Canada’s Pest Management Regulatory Agency (PMRA).

About dsRNA
dsRNA is part of a process called RNA interference (RNAi) that occurs naturally in plants, animals and fungi. In RNAi, dsRNA molecules moderate gene expression by binding to a matching sequence of a “target” messenger RNA (mRNA), causing it to be destroyed. In other words, dsRNA transiently “silences” the expression of genes. This process can be harnessed for use in pest control applications by designing sequence-specific dsRNA to target mRNA encoding, for example, a protein that may be essential for the survival, reproduction, or growth of a pest. It could also be used to eliminate proteins that contribute to a pest exhibiting resistance to a conventional pest control product.

Current uses
Novel foods harnessing RNAi (for example, corn expressing a dsRNA that causes death in Western Corn Rootworm) have already been approved for use in food and feed by Health Canada’s Health Products and Food Branch and by the Canadian Food Inspection Agency, respectively. However, dsRNA-based pesticides would differ from these novel foods in that dsRNA molecules would be applied directly to the crop (for example, by spraying), instead of the crop itself producing the dsRNA.

Current regulatory status
dsRNA-based pesticides are an active field of research and development, and applications for registration of dsRNA-based pesticides are expected in Canada. Health Canada’s PMRA has completed pre-submission consultations and has been granting research authorizations for experimental trials of dsRNA-based pesticides since 2016. For more information on research involving dsRNA-based pesticides, please contact the PMRA’s Pest Management Information Service.

The use of dsRNA in pest control applications meets the Pest Control Products Act definition of “pest control product”, and therefore is subject to regulation by the PMRA as a novel class of pesticides. dsRNA does not fall under any of the existing frameworks for conventional or microbial active ingredients, pheromones or semiochemicals, etc.; therefore, data requirements for dsRNA-based pesticides are currently being determined on a case-by-case basis.

To date, the PMRA has not received any applications with data to support the registration of dsRNA-based pest control products. Sufficient data to assess any potential hazards and risks associated with dsRNA-based pesticides, such as data on toxicology, occupational and dietary exposure and hazard to non-target organisms in the environment, as well as their value, would need to be evaluated by the PMRA to determine if registration of such products could be approved.

Until such data are submitted and assessed, the use of dsRNA-based pesticides is not permitted under the Pest Control Products Act, except for research that has been approved by the PMRA under a research authorization.

Current actions
In anticipation of data development, the PMRA is working with international partners and stakeholders through the Organisation for Economic Co-Operation and Development (OECD) within the Ad Hoc Expert Group on RNAi-based Pesticides. This OECD Expert Group has developed documents on topics to consider in order to determine if risks associated with the use of dsRNA-based pesticides will be acceptable for human health and the environment.

In addition, the PMRA offers a free pre-submission consultation service that provides regulatory guidance to applicants prior to the submission of an application. To request a pre-submission consultation or to obtain additional information on submitting an application relating to a dsRNA-based pest control product, contact the PMRA at pmra.presubs-prealables@hc-sc.gc.ca.

For more information

Pesticides in Canada
Registrants and Applicants
Research Authorizations and Notifications
Pest Management Information Service
OECD Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, Pesticides and Biotechnology, Series on Pesticides No. 104 – Considerations for the Environmental Risk Assessment of the Application of Sprayed or Externally Applied dsRNA-Based Pesticides
OECD Chemicals and Biotechnology Committee, Series on Pesticides No. 110 – Considerations for the Human Health Risk Assessment of Externally Applied dsRNA-Based Pesticides

Clarification regarding fake websites


It has come to the notice of the Ministry of Education that in order to dupe innocent applicants several websites have been created with the name similar to the schemes (like www.sarvashiksha.online, https://samagra.shikshaabhiyan.co.in, https://shikshaabhiyan.org.in)  of this Department. 


These websites are offering employment opportunities to the aspiring candidates and misguiding the job aspirants through the layout of website, content and presentation in a manner similar to original website and asking for money from the respondents for the applications. While, these websites have come to the notice of the Department of School Education and Literacy, there may be more such other websites/social media accounts promising jobs and demanding money for recruitment process. 


 The General Public is, hereby, advised to avoid applying for job opportunities on such websites and to ensure themselves that the websites are authorised by visiting the official website of the concerned Department/personal inquiry/telephone call/e-mail to safeguard their own interest. Any person applying on these websites will be doing so at his own risk & cost and shall be responsible for the consequences thereof.


*****


MJPS/AK




(Release ID: 1803647)
Visitor Counter : 188













Notice Regarding Changes in Representative Corporate Executive Officers

WEBWIRE



Mitsubishi Chemical Holdings Corporation (MCHC) hereby announces that its Board of Directors meeting today passed a resolution on personnel changes with regard to the Representative Corporate Executive Officer as detailed below.


1. Current and New Representative Corporate Executive Officers


New Position / Current Position / Name


Executive Vice President – Head of Petrochemical and Coal business / Representative Managing Corporate. Executive Officer, Supervising Corporate Strategy, Division, Corporate Communications. Office (Branding) / Yoshihiro Ikegawa



Representative Corporate Executive Officer, Executive Vice President, Chief Supply Chain Officer / Representative Director, Director of the Board, Managing Executive Officer, Supervising- Supply Chains, Mitsubishi Chemical Corporation /Nobuo Fukuda


2. Biography of the New Representative Corporate Executive Officer


Nobuo Fukuda  – (Date of Birth: December 9, 1958  – Number of shares held: 21,074)


1981 Joined Mitsubishi Chemical Industries Limited (currently, Mitsubishi Chemical Corporation)


2012 General Manager, Kurosaki Plant, Mitsubishi Chemical Corporation


2014 Executive Officer, General Manager of Chemical Products, Mitsubishi Chemical Corporation


2021 Representative Director, Director of the Board, Managing Executive Officer supervising- Supply Chains, Mitsubishi Chemical Corporation (current position)


3. Scheduled Date of Personnel Changes


April 1, 2022


4. Reason for the Personnel Changes


Changes in the management structure


In its new management policy “Forging the future” announced on 1 December 2021, MCHC announced its management structure from 1 April 2022. For more details, please refer to the attached press release “4. Leaner Structure to Execute Strategy”.


https://www.mitsubishichem-hd.co.jp/english/ir/01168.html


Corporate Executive Officers of MCHC from 1 April 2022 onwards is shown in the Annex.


Annex


Corporate Executive Officers (as of April 1, 2022)


Representative Corporate Executive Officer, President and Chief Executive Officer Jean-Marc Gilson Representative Corporate Executive Officer, Executive Vice President Chief Supply Chain Officer – Nobuo Fukuda

Executive Vice President, Chief Financial Officer Supervising – finance, communication, IR and government affairs – Yuko Nakahira

Executive Vice President, Chief Compliance Officer General Counsel Supervising – legal, internal control, admin, HR and corporate administration – Ken Fujiwara

Executive Vice President Head of Films & Molding Materials / Advanced Solutions Johei Takimoto Executive Vice President Head of Polymers & Compounds / MMA Hitoshi Sasaki Executive Vice President Head of Petrochemical & Coal business – Yoshihiro Ikegawa

Executive Vice President Head of Pharma Hiroaki Ueno Senior Vice President, Chief Technology Officer – Larry Meixner

Senior Vice President Supervising – government affairs –  Shigeki Habuka


Corporate Executive Officers supervising digital and audit will be decided in due course


Notice Regarding Biogen’s Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer’s Disease

Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer’s disease, in countries other than the United States, Japan, and in Europe which have been announced previously.

In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer’s disease. This application is currently in queue for review.

Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.

Aducanumab is being jointly developed by Biogen and Eisai.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary